The Kano trovafloxacin trial litigation arose out of a clinical trial conducted by the .... ever been treated with Trovan, and then only after all other antibiotics failed.
Summary of this case from Kiobel v. .... Pfizer International, Inc.,  Suit No. ..... M. Cheriff Bassiouni et al., An Appraisal of Human Experimentation in ...
Jan 19, 2018 ... In Wyeth v. Levine, the Supreme Court held that claims against a manufacturer of a brand-name prescription drug for failure to warn adequately ...
Jul 27, 2017 ... Palbociclib (IBRANCE®; Pfizer Inc, New York, NY, USA) is a new oral cyclin- dependent kinase ... All references used in two previous NMAs by Generali et al. .... Model fit statistics, Residual deviance = 25.08 vs. ..... Migliaccio I, Malorni L, Hart CD, Guarducci C, Di Leo A. Endocrine therapy considerations in ...
Jul 29, 2010 ... For all markers, the pan-cytokeratin signal was used to create an epithelial “mask ” to distinguish .... to those tumors with squamous cell histology (Figure 3B (SQ), median AQUA scores 5,885 vs. ..... Disclosures: This research was supported by Pfizer Inc. ... Gustavson MD, Bourke-Martin B, Reilly DM, et al.
7/13/2016 · 3:16-cv-03922 · Schaaf-Richards v. Volkswagen Group of America, Inc. et al ...... 3:07-cv-06497-CRB · Abad v. Bronson & Migliaccio. LLP et al ...
Of these, 5.8% switched, 51.3% permanently discontinued all anticholinergic agents, and .... Detrol, Detrol LA and Toviaz (Pfizer Inc., New York, New York). ‡ .... switches are almost one third the rate observed by D'Souza et al (5.8% vs 13 %). ... Ms. Migliaccio-Walle led the manuscript preparation, provided oversight and ...
Mar 10, 2016 ... postmenopausal patients with all stages of ER ю breast cancer (1). ...... Luca Malorni, Mario Giuliano, Ilenia Migliaccio, et al. Resistance.
Mar 5, 2015 ... Ilenia Migliaccio,; Luca Malorni,; Christopher D Hart,; Cristina Guarducci and; Angelo Di LeoEmail ... Migliaccio et al.; licensee BioMed Central.